3 years 4.62
Extreme 4.62
28.26
5 years 4.62
Extreme 4.62
59.99
10 years 4.62
Extreme 4.62
195.97
Manager TitleAgeSince
President 65 30/07/2025
General Counsel - 31/07/2020
Director TitleAgeSince
Director/Board Member 65 30/07/2025
Date Insider Type Main position Quantity % Market Cap. Importance
31/07/25 Issuer sale

Director

21,500 0.0350%
31/07/25 Issuer sale

Chief Technology Officer

72,961 0.1187%
31/07/25 Tender

Director

43,499 0.0708%
Change 5-day change 1-year change 3-year change Capi.($)
-0.23%-.--% - - 544M
-4.83%+2.88%+55.87%+69.12% 69.4B
+0.02%+1.07%+10.63%+76.66% 57.24B
-1.34%+2.98%+24.79%+100.18% 57.62B
+2.56%+1.85%+29.12%+37.23% 43.65B
+5.61%+10.63%+23.27%+108.88% 44.03B
+8.60%+1.05%+214.95%+797.47% 38.08B
-1.86%+11.46%+26.67%+61.40% 36.31B
-2.97%-9.84%+88.86%+76.17% 32.61B
-2.18%+5.68%+36.21%-0.69% 25.47B
Average +0.35%+2.24%+56.71%+147.38% 44.93B
Weighted average by Cap. +0.16%+2.44%+52.38%+139.55%
Logo Sage Therapeutics, Inc.
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed two FDA-approved treatments indicated for postpartum depression (PPD) and is advancing a portfolio of internally discovered novel chemical entities with the potential to become differentiated treatments designed to improve brain health by primarily targeting two critical central nervous system, receptor systems, GABA and NMDA. Its product ZURZUVAE is for the treatment of PPD in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, and is the first oral, once-daily, 14-day treatment specifically indicated for adults with PPD. It is also evaluating potential indications for SAGE-324, a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing, including seizures in developmental and epileptic encephalopathies. Its other areas of focus are SAGE-319, SAGE-039, and SAGE-817.
Employees
353
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Sage Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. SAGE Stock